Corcept Therapeutics Surges on Early FDA Approval for Ovarian Cancer Drug Lifyorli

Corcept Therapeutics (CORT) has received early approval from the U.S. Food and Drug Administration (FDA) for its oncology drug Lifyorli, targeting platinum-resistant ovarian cancer. Clinical data revealed that the drug demonstrated a significant 35% reduction in the risk of death while maintaining strong tolerability among patients. Following this milestone, the company issued optimistic sales guidance for 2026, projecting revenues between $900 million and $1 billion. Analysts have subsequently upgraded the stock's rating, noting that Lifyorli is well-positioned to offset the declining sales of the company's older product, Korlym. This development marks a major shift in Corcept's long-term revenue outlook and overall market valuation. The approval underscores the growing strength of the company's biotech pipeline and its potential for sustained growth in the oncology sector.